There are several new therapies available to treat men with advanced prostate cancer;
however, the decision making tools needed to determine the best treatment for these patients
are noticeably absent. The prostate-specific membrane antigen (PSMA) is increasingly being
recognized as an important target for prostate cancer imaging and determining the most
effective therapy. Accordingly, a wide variety of agents are being used to image PSMA. One of
these agents is 18F-DCFPyL. In this study the investigators will image men with advanced
prostate cancer using 18F-DCFPyL and a positron emission computed tomography (PET/CT)
scanner. The investigators will compare the results of 18F-DCFPyL PET/CT for the detection of
metastases and monitoring the effects of therapy with conventional imaging (CT, bone scan)
and clinical follow-up. In this way, the investigators will evaluate the benefit of using
18F-DCFPyL PET/CT to decide what is the best treatment strategy for a man with advanced
prostate cancer.